GlassScriptPhysician profile
Scott J Arbaugh
NPI 1861553513
$160,897.21
in general payments reported to CMS, 2019-2025
36 companies · $35K in 2025
The $35K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $13K · 2021: $18K · 2022: $16K · 2023: $19K · 2024: $38K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Food and Beverage: $9,058 · Travel and Lodging: $4,269 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,906.25 |
| Food and Beverage | $9,057.70 |
| Travel and Lodging | $4,268.73 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $121,629.51 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $15,060.91 | 2021-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $8,107.04 | 2019-2022 | |
| Allergan, INC. | $5,665.41 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $1,994.89 | 2019-2021 | |
| Lundbeck LLC | $1,497.10 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,214.22 | 2020-2025 | Caplyta |
| Validus Pharmaceuticals LLC | $884.37 | 2019-2025 | Equetro, Equetro, Raldesy |
| Alkermes, INC. | $754.81 | 2020-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $642.66 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $580.48 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $578.82 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $493.38 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $226.27 | 2022-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $190.80 | 2019-2025 | Fanapt |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $157.33 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $154.06 | 2025 | Jornay Pm |
| Shire North American Group INC | $148.50 | 2019 | |
| Sage Therapeutics, LLC | $125.64 | 2024-2025 | Zurzuvae |
| Eisai INC. | $86.51 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $84.82 | 2019-2024 | Austedo Xr, Austedo |
| Corium, LLC | $84.51 | 2023-2024 | Azstarys |
| Noven Therapeutics, LLC | $83.64 | 2024-2025 | Xelstrym, Secuado |
| Biogen, INC. | $72.06 | 2020-2021 | |
| Tris Pharma INC | $63.11 | 2022-2023 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $61.88 | 2021-2023 | Belsomra |
| Adlon Therapeutics L.P. | $57.56 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $38.94 | 2024 | |
| Almatica Pharma LLC | $29.61 | 2021-2022 | |
| Neos Therapeutics, LP | $26.91 | 2020 | |
| Avanir Pharmaceuticals, INC. | $21.66 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.43 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.09 | 2025 | |
| Lilly USA, LLC | $17.94 | 2025 | Kisunla |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.01 | 2023 | |
| Arbor Pharmaceuticals, INC. | $11.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Arbaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.